Changes in Beneficial Ownership · 4
Avalyn Pharma Inc.
AVLNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-09
- Issuer
- Avalyn Pharma Inc.
- Issuer CIK
- 0001540171
- Trading symbol
- AVLN
Reporting owner 1
- Name
- FMR LLC
- Reporting owner CIK
- 0000315066
- Relationship
- 10% owner · Other
- Other relationship
- See Remark 1
- Address
- 245 SUMMER STREET, BOSTON, MA, 02210
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-09 | S · Form 4 | 173,661 | D | 29.06[F1] | 2,110,874 | I | F-Prime Capital Partners Healthcare Fund V LP |
| Common Stock | 2026-11-09 | S · Form 4 | 1,339 | D | 29.75[F2] | 2,109,535 | I | F-Prime Capital Partners Healthcare Fund V LP |
| Common Stock | 2026-11-10 | S · Form 4 | 5,565 | D | 29.56[F3] | 2,103,970 | I | F-Prime Capital Partners Healthcare Fund V LP |
| Common Stock | 2026-11-10 | S · Form 4 | 47,889 | D | 30.28[F4] | 2,056,081 | I | F-Prime Capital Partners Healthcare Fund V LP |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Disposed
- I
- Indirect
Footnotes
- F1
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.65 to $29.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.↩ 1
- F2
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.68 to $29.83. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.↩ 1
- F3
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.82 to $29.81. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.↩ 1
- F4
- The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.82 to $30.62. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.↩ 1
Remarks
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager.
Signature 1
- Signed
- /s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
- Date
- 2026-11-12
Company context
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.